Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-stake validation, reflected in the fund's net asset value. Injective is a Layer-1 blockchain designed for on-chain finance, supporting tokenization, trading, and financial applications with over 1 billion in tokenized assets and significant transaction volume. This ETF allows investors to access INJ through traditional brokerage accounts while benefiting from the blockchain's financial infrastructure innovations and staking potential.
The Canary Staked INJ ETF launch provides exposure to INJ, a token from the Injective blockchain, which supports over 1 billion in tokenized assets. For readers following US stocks, here is Pluang's market snapshot as of Nov 06, 2026 20:21 WIB: out of 150 priced stocks, 60 rose and 85 fell. Notable movers include INTC at USD 55.05 with a 1-day change of +5.36%, FCEL at USD 9.40 with +5.26%, and SNOW at USD 283.28 with +5.10%.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...
